Document:

License Agreement

 EXHIBIT 10.7 
 2/8/95 
 MK:dcr 
 CMS.Agr 
 LICENSE AGREEMENT 
 This AGREEMENT is effective as of the 8th day of February 1995, between California Institute of Technology, 1201 East
California Boulevard, Pasadena, California 91125 (“CALTECH”) and Clinical Micro Sensors, Inc., 428 South Sierra Bonita Avenue, Pasadena, CA 91106 (“CMS”), a corporation of the State of California: 
 WHEREAS, CALTECH, has been engaged in basic research relating to nucleic acid mediated electron transfer and cell and
tissue-specific MRI contrast agents; 
 WHEREAS, CALTECH owns full right, title and interest in United States
Patent Application Number 08/166,036 filed December 10, 1993 entitled “Nucleic Acid Mediated Electron Transfer” (CIT 2222) and to an invention entitled “Cell and Tissue-Specific MRI Contrast Agents” (CIT 2223) which will be
the subject of a United States Patent Application and has the requisite power and authority to enter into this Agreement and to convey to CMS the interests herein; 
 WHEREAS, currently herewith CALTECH is receiving a *** equity interest in CMS; 
 WHEREAS, CMS, is desirous of an exclusive license to the aforementioned United

  

	***	 Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.

 
States Patent Application and invention, and to certain divisions, continuations and continuation-in-part applications of the aforementioned application. 
 NOW, THEREFORE, the parties agree as follows: 
 ARTICLE I 
 DEFINITIONS 
 1. “Subject Technology” means any, product or process covered by any claim in a Licensed Patent. 
 2. “Licensed Method” means any process or method, the use or practice of which would constitute an infringement of
a valid claim of a Licensed Patent in that country in which the Licensed Method is used or practiced. 
 3.
“Licensed Product” means (a) any product which cannot be manufactured, used or sold without infringing a valid claim of a Licensed Patent or (b) the practice of the Licensed Method. 
 4. “Licensed Patent” means any patent issued from the aforementioned United States Patent Application and
invention and any continuation, continuation-in-part, divisions, reissues, re-examinations, and any foreign counterparts thereof. 
 5. “Deductible Expenses” means all costs incurred in connection with sales of Licensed Products to the extent paid or allowed by CMS and included in accordance with recognized principles of
accounting in the gross sales price billed: (i) sales, use or turnover taxes; (ii) excise taxes, custom duties or consular fees; (iii) transportation, freight, and handling charges, and insurance on shipments to customers;
(iv) trade or quantity discounts to the extent

  

 2 

 
actually granted; (v) agent fees or commissions and (vi) rebates, refunds, and credits for any returned Licensed Products. 
 6. “Related Company” means any company directly or indirectly controlled by, controlling, or under common control
with CMS. 
 ARTICLE II 
 PATENT LICENSE GRANT 
 7. CALTECH hereby grants to CMS and
any Related Company an exclusive license to make, have made, use, distribute and sell Licensed Products throughout the world, subject to the reservation of CALTECH’s right, on the part of itself and the Jet Propulsion Laboratory, to make, have
made, and use Licensed Products solely for educational and research purposes. This license is not transferable by CMS, but CMS shall have the right to grant sublicenses provided that: 
 (A) In the event CMS receives any licensing fees or royalty payments from the sublicensing by CMS of this Agreement
including running royalty payments from its sublicensees, CALTECH shall receive *** of all such fees or payments. 
 (B) CMS shall furnish CALTECH within thirty (30) days of the execution thereof, a true and complete copy of each sublicense and any changes or additions thereto. 
 (C) In the event that CALTECH terminates this License Agreement because of a material breach by CMS which is not cured by CMS within the time specified in Article VI

  

	***	 Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.

  

 3 

 
then CALTECH shall offer Molecular Dynamics a license ssubstantially identical to the sublicense to be negotiated between CMS and Molecular Dynamics. 
 8. The exclusive patent license shall continue until the last of the Licensed Patents expires. 
 ARTICLE III 
 CMS
PAYMENTS 
 9. (A) Starting from the issue date of the Licensed Patent and for the full term of the
exclusive patent license granted under Article II, CMS shall pay to CALTECH patent royalty payments of *** of the gross sale of Licensed Products. The above royalty percentage is to be applied to gross sales after Deductible Expenses for any
Licensed Products sold by CMS, its agents, its distributors, or Related Companies. 
 (B) CMS agrees that
provided a patent has issued it will pay a minimum *** . 
 (C) CMS shall reimburse CALTECH for all expenses
associated with the preparation, filing, prosecution and maintenance of any foreign equivalents of the Licensed Patent that CMS directs CALTECH to file. With respect to all costs paid through Chapter II of PCT, CMS will reimburse CALTECH within ***
years of the effective date of this Agreement. All subsequent costs shall be reimbursed within thirty days of the receipt of a CALTECH statement by CMS. 
  

	***	 Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.

  

 4 

 ARTICLE IV 
 UNLICENSED MANUFACTURE, USE OR SALE BY INFRINGERS 
 10. In
the event either CMS or CALTECH discovers any unlicensed manufacture, use or sale of Licensed Products, the other party shall be promptly notified of such infringement. CMS may, at its own option and at its own expense, through attorneys of its own
election, take appropriate action to terminate or prevent the infringement provided, however, that CMS may not bring an action nor enter into any settlement agreement with an accused infringer without prior written approval of CALTECH, which
approval will not be unreasonably withheld. CALTECH agrees to be joined as a party plaintiff to any such action. If CMS takes no action within ninety (90) days of the discovery of the infringement, then CALTECH at its option, may take such
action as it deems appropriate including but not limited to the right to license others to make, use and sell the Licensed Products. 
 11. CALTECH shall not be obligated to bring suit for infringement nor have any responsibility for taking or defending any action whatsoever against or by infringers or alleged infringers; provided,
however, that CALTECH shall have the right and option upon giving of written notice to CMS, to participate in any such action, to contribute funds to the prosecution of such action, and to be represented by counsel. Furthermore, CALTECH shall not be
obligated to defend the Licensed patents or any claim thereof against challenge or attack by any third party in the United States Patent & Trademark Office or the courts or elsewhere. 
 12. If CMS engages in litigation or otherwise incurs expense in order to terminate infringement and receives any money by
way of damages, license or otherwise as a result of

  

 5 

 
such action, then to the extent that such money exceeds the expense involved, *** of the excess shall be shared with CALTECH. 
 13. If any claim that CMS’s practice of the Licensed Patent, in connection with the manufacture and/or sale of Licensed
Product, infringes any patents or proprietary rights of any third party, is brought against CMS or its sublicensees, prompt notice of the claim asserted shall be given by CMS to CALTECH. The defense against any such claim will be conducted by CMS at
its expense, but CALTECH may have counsel present at its own expense and shall be entitled to participate in the defense of any such claim. No settlement of any such matter, where CALTECH is party to the claim or a defendant, shall be made without
the written approval of CALTECH, which approval shall not be unreasonably withheld. During the pendency of any such claim brought against CMS or its sublicensee, royalties due under this Agreement with respect to manufacture and/or sale of Licensed
Product in the country of the disputed Patent Rights shall accrue, but not be paid. Such accrued royalties, less all expenses incurred by CMS as a result of such claims, shall be paid to CALTECH upon its successful defense of such claims or upon the
settlement thereof with the approval of CMS, which approval shall not be unreasonably withheld. 
 ARTICLE V 
 RECORDS, REPORTS AND PAYMENTS 
 14. CMS shall keep records and books of account in respect of all Licensed Products made and sold by CMS under this agreement, and CMS shall require the same in respect to sales by its distributors,
agents, and related companies. CALTECH shall have the right at its expense,

  

	***	 Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.

  

 6 

 
during business hours, to examine, or to have its designated auditors examine, such records and books of account, and CMS shall keep the same for at least three years after it pays CALTECH the
royalties due for such Licensed Products and require Related Buyers to do the same. 
 15. On or before the
forty-fifth day after the close of each calendar quarter after the first commercial sale, CMS shall render to CALTECH a report in writing, setting forth the number of units of Licensed Products manufactured and the number of units sold during the
preceding calendar quarter by CMS and its distributors, agents and related companies, and also setting forth all information necessary to determine the royalties payable hereunder, such report to be accompanied by payment of the royalties shown by
said report to be due CALTECH. Royalties and royalty reports for sales by sublicensees are due in the quarter after receipt of such payments and reports by CMS from its sublicensees. 
 ARTICLE VI 
 TERMINATION 
 16. If either party breaches in any material respect any of its obligations hereunder, the other party shall have the right
to terminate this agreement and the license granted hereunder by giving the breaching party ninety (90) days written notice thereof, provided, however, that if the breaching party cures the breach within such ninety (90) day period, this
agreement shall continue in full force and effect. CMS shall have the right to terminate this agreement at any time after it makes all payments and submits all reports to CALTECH due hereunder by giving CALTECH sixty (60) days written notice.
CMS shall have the right to sell inventory on hand at the time of termination. 
 17. No termination of this
agreement shall relieve CMS of the liability for payment of

  

 7 

 
any royalty due for Licensed Products made prior to the effective date of such termination. 
 ARTICLE VII 
 NEGATION OF WARRANTIES, IMPLIED LICENSES, AND AGENCY

 18. Nothing in this agreement shall be construed as: 
 (A) a warranty or representation by CALTECH as to the validity or scope of Subject Technology or any claim thereof; or

 (B) a warranty or representation that anything made, used, sold, or otherwise disposed of hereunder is or
will be free from infringement of rights of third parties; or 
 (C) an obligation to bring or prosecute actions
or suits against third parties for infringement, except to the extent provided in ARTICLE IV; or 
 (D)
conferring by implication, estoppel or otherwise, any license or rights under any patents of CALTECH other than Licensed Patent, regardless of whether such other patents are dominant or subordinate to Licensed Patent. 
 19. NEITHER CALTECH NOR CMS MAKES ANY EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.

 20. CALTECH and CMS are independent parties in this agreement. Accordingly, there is no agency relationship
between CALTECH and CMS under this agreement with respect to any products made or sold, or any methods used, by CMS under this agreement. 
 ARTICLE VIII 
 MISCELLANEOUS 
 21. CMS agrees that it will not use the name of CALTECH, or California Institute of

  

 8 

 
Technology, in any advertising or publicity material, or make any form of representation or statement which would constitute an express or implied endorsement by CALTECH of any commercial product
or services, and that it will not authorize others to do so, without first having obtained written approval from CALTECH. CMS further agrees that the name of any inventor or employee of CALTECH will not be used by CMS in any such advertising or
publicity material without the prior written consent of such inventor or employee. 
 22. CMS agrees to mark
when reasonably possible the appropriate U.S. patent number or numbers on all Licensed Products made under this agreement and to require its sublicensees to do the same. 
 23. CMS agrees that CALTECH shall have no liability to CMS or to any purchasers or users of Licensed Products made or sold by CMS for any claims, demands, losses, costs, or damages
suffered by CMS, or purchasers or users of Licensed Products, or any other party, which may arise out of the manufacture, use, or sale of such Licensed Products, and CMS agrees to defend, indemnify, and hold harmless CALTECH, its trustees, officers,
agents, and employees from any such claims, demands, losses, costs, or damages. 
 24. This contract includes
all the agreements of the parties in respect to the subject matter hereof. No claimed oral agreement in respect thereto shall be considered as any part hereof. No waiver of or change in any of the terms hereof subsequent to the execution hereof
claimed to have been made by any representative of either party shall have any force or effect unless in writing, signed by duly authorized representatives of the parties. 
 25. This agreement shall be binding upon and inure to the benefit of any successor or assignee of CALTECH. This Agreement is not assignable by CMS or by operation of law 

 

 9 

 
without the prior written consent of CALTECH, which consent shall not unreasonably be withheld, except that CMS may assign the agreement to any successor of its business, or purchaser of
substantially all of the assets of its business, to which this agreement pertains. Should CMS be declared bankrupt following the filing of a petition in bankruptcy, be declared insolvent or execute an assignment for the benefit of creditors, or
should a receiver or trustee be appointed by any court or government agency to administer the affairs and assets of CMS, then, in that event, this agreement shall become terminated, unless the receiver, or trustee, or other assignee, at the time of
the assumption of this agreement: (a) cures defaults, if any, or gives reasonable assurance that any such defaults will be timely cured; and (b) provides adequate assurance of future performance under this agreement. 
 26. This agreement shall be deemed to have been entered into in California and shall be construed and enforced in accordance
with California law. 
 27. Any controversy or claim arising out of or relating to this contract, or the breach
thereof, including any dispute relating to patent validity or infringement arising under this contract, shall be settled by arbitration in Los Angeles, California or other site of CMS headquarters in accordance with the Patent Arbitration Rules of
the American Arbitration Association, and judgment upon the award rendered by the Arbitrator may be entered in any Court having jurisdiction thereof. 
 28. Any notice or communication required or permitted to be given or made under this agreement shall be addressed as follows: 
  

 10 

					
	 CALTECH:
	 		  	 Office of Patents & Licensing

		 		  	 California Institute of Technology

		 		  	 1201 East California Boulevard, MC 305-6

		 		  	 Pasadena, California 91125

		 		  	 Fax No. (818) 577-2528

			
	 CMS:
	 		  	 Clinical Micro Sensors, Inc.

		 		  	 428 South Sierra Bonita Avenue

		 		  	 Pasadena, CA 91106

		 		  	 Fax No. (818) 584-9150

 All communications relative to this agreement shall be deemed to be duly received seven days after mailing or upon actual receipt, whichever is earlier, if sent by Certified Mail, Return Receipt
Requested, to the above address, and shall be deemed received the day after transmission if sent by a graphic scanning process (FAX) to the above number, unless either party is notified by the other in writing of a change of address or FAX number,
in which event any subsequent communication relative to this agreement shall be sent to the last said notified address or number. 
  

 11 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed by their duly authorized officers. 
  

			
	CALIFORNIA INSTITUTE OF TECHNOLOGY (CALTECH)
		
	 By:
	 	 /s/ Brian K. Jenkins

	 Name:
	 	 Brian K. Jenkins

	 Title:
	 	 Assistant Director of Finance

		
	 Date:
	 	 February 8, 1995

	
	 CLINICAL MICRO SENSORS, INC. (CMS)

		
	 By:
	 	 /s/ Jon Faiz Kayyem

	 Name:
	 	 Jon Faiz Kayyem

	 Title:
	 	 President, C.E.O.

		
	 Date:
	 	 February 8, 1995

  

 12Amended and Restated License Agreement

 EXHIBIT 10.8 
 AMENDED AND RESTATED 
 LICENSE AGREEMENT 
 BETWEEN 
 PRESIDENT
AND FELLOWS OF HARVARD COLLEGE 
 AND 
 CLINICAL MICRO SENSORS, INC 
 Effective as of July 14, 1997 
 Re: Harvard Case No(s). 1063 and 1339 
 In consideration of the mutual promises and covenants set forth below, the parties hereto agree as follows: 
 ARTICLE I 
 BACKGROUND 
 HARVARD has entered into an agreement, effective July 14, 1997 (“the License Agreement”), with LICENSEE
granting LICENSEE certain rights under PATENT RIGHTS. The parties hereto agree that this Amended and Restated License Agreement supercedes and replaces the July 14, 1997 License Agreement. 
 ARTICLE II 
 DEFINITIONS 
 As used in this Agreement, the following terms shall have the following meanings:

  

	2.1	 AFFILIATE: any company, corporation, or business (a) which owns or controls at least fifty percent (50%) of the voting stock or other
ownership of LICENSEE; or (b) of which LICENSEE owns or controls at least fifty percent (50%) of the voting stock or other ownership. Unless otherwise specified, the term LICENSEE includes AFFILIATES. 

  

	2.2	 EFFECTIVE DATE: shall mean July 14, 1997 

  

	2.3	 FIELD: shall mean all fields of use 

  

	2.4	 HARVARD: President and Fellows of Harvard College, a nonprofit Massachusetts educational corporation having offices at the Office for Technology and
Trademark Licensing, 124 Mt. Auburn Street, Suite 410 South, Cambridge, Massachusetts 02138. 

	2.5	 LICENSED PROCESSES: the processes covered by PATENT RIGHTS. 

  

	2.6	 LICENSED PRODUCTS: products covered by PATENT RIGHTS or products made or services provided in accordance with or by means of LICENSED PROCESSES.

  

	2.7	 LICENSEE: Clinical Micro Sensors, Inc a corporation organized under the laws of California having its principal offices at 101 Waverly Drive,
Pasadena, CA 91105. 

  

	2.8	 NET SALES: the amount billed, invoiced, or received (whichever occurs first) for sales, leases, or other transfers of LICENSED PRODUCTS, less:

  

	 	(a)	 customary trade, quantity or cash discounts and non-affiliated brokers’ or agents’ commissions actually allowed and taken;

  

	 	(b)	 amounts repaid or credited by reason of rejection or return; and 

  

	 	(c)	 to the extent separately stated on purchase orders, invoices, or other documents of sale, taxes levied on and/or other governmental charges made as
to production, sale, transportation, delivery or use and paid by or on behalf of LICENSEE or sublicensees. 

  

	 	(d)	 reasonable charges for delivery or transportation provided by third parties, if separately stated. 

 NET SALES also includes the fair market value of any non-cash consideration received by LICENSEE or sublicensees for the
sale, lease, or transfer of LICENSED PRODUCTS. 
  

	2.9	 NON-COMMERCIAL RESEARCH PURPOSES: use of PATENT RIGHTS for academic research or other not-for-profit scholarly purposes which are undertaken at a
non-profit or governmental institution that does not use the PATENT RIGHTS in the production or manufacture of products for sale or the performance of services for a fee. 

  

	2.10	 NON-ROYALTY SUBLICENSE INCOME: Sublicense issue fees, sublicense maintenance fees, sublicense milestone payments, and similar non-royalty payments
made by sublicensees to LICENSEE on account of sublicenses pursuant to this Agreement. 

  

	2.11	 PATENT RIGHTS: United States patents and patent applications listed in Appendix A, including USSN Serial No. 08/312,388 filed 9/26/94, entitled
“Molecular Recognition at Surfaces Derivatized with Self Assembled Monolayers” and United States patent application entitled “Surface-Immobilized Nucleic Acid and Electron-Transfer Devices and Methods”, filed on 1/21/97, the
inventions described and claimed therein, and any divisions, continuations, continuations-in-part to the extent the claims are directed to subject matter

	 	 
specifically described and dominated by the claims of the existing PATENT RIGHTS, patents issuing thereon or reissues thereof, and any and all foreign patents and patent applications
corresponding thereto, all to the extent owned or controlled by HARVARD. 

  

	2.12	 TERRITORY: Any and all countries for which PATENT RIGHTS exist. 

  

	2.13	 The terms “Public Law 96-517” and “Public Law 98-620” include all amendments to those statutes. 

  

	2.14	 The terms “sold” and “sell” include, without limitation, leases and other transfers and similar transactions.

 ARTICLE III 
 REPRESENTATIONS 
  

	3.1	 HARVARD is sole owner by assignment from Drs. C. Bamdad, J. Strominger, G. Sigal and G. Whitesides of their entire right,
title and interest in United States Patent Application Serial No. 08/312,388 filed 9/26/94 entitled ‘Molecular Recognition at Surfaces Derivatized with Self Assembled Monolayers’ (H.U. Case #1063) and from Dr. C. Bamdad of
her entire right title and interest in United States Patent Application entitled ‘Surface-Immobilized Nucleic Acid and Electron Transfer Devices or Methods filed 1/21/97 (HU Case #1339) in the foreign patent applications corresponding thereto,
and in the inventions described and claimed therein. 

  

	3.2	 HARVARD has the authority to issue licenses under PATENT RIGHTS. 

  

	3.3	 HARVARD warrants that all intellectual property rights to HU Case nos. 1063 and 1339 are included in PATENT RIGHTS. 

  

	3.4	 HARVARD is committed to the policy that ideas or creative works produced at HARVARD should be used for the greatest possible public benefit, and
believes that every reasonable incentive should be provided for the prompt introduction of such ideas into public use, all in a manner consistent with the public interest. 

  

	3.5	 LICENSEE is prepared and intends to diligently develop the invention and to bring products to market which are subject to this Agreement.

  

	3.6	 LICENSEE is desirous of obtaining an exclusive license in the TERRITORY and in the FIELD in order to practice the above-referenced invention covered
by PATENT RIGHTS in the United States and in certain foreign countries, and to manufacture, use and sell in the commercial market the products made in accordance therewith, and HARVARD is desirous of granting such a license to LICENSEE in accordance
with the terms of this Agreement. 

 ARTICLE IV 
 GRANT OF RIGHTS 
  

	4.1	 HARVARD hereby grants to LICENSEE and LICENSEE accepts, subject to the terms and conditions hereof an exclusive commercial license in the TERRITORY
and in the FIELD under PATENT RIGHTS to make and have made, to use and have used, to sell and have sold the LICENSED PRODUCTS, and to practice the LICENSED PROCESSES, for the life of the PATENT RIGHTS. Such licenses shall include the right to grant
sublicenses, subject to HARVARD’s review. In order to provide LICENSEE with commercial exclusivity for so long as the license under PATENT RIGHTS remains exclusive, HARVARD agrees that it will not grant licenses under PATENT RIGHTS to others
except as required by HARVARD’s obligations in paragraph 3.2(a)or as permitted in paragraph 3.2(b). 

  

	4.2	 The granting and exercise of this license is subject to the following conditions: 

  

	 	(a)	 HARVARD’s “Statement of Policy in Regard to Inventions, Patents and Copyrights,” dated March 17, 1986, Public Law 96-517, Public
Law 98-620, and HARVARD’s obligations under agreements with other sponsors of research. To the best of HARVARD’s knowledge, the only sponsor of the research from which PATENT RIGHTS arise is the federal government. Any right granted in
this Agreement greater than that permitted under Public Law 96-517, or Public Law 98-620, shall be subject to modification as may be required to conform to the provisions of those statutes. 

  

	 	(b)	 HARVARD reserves the right to make and use, and grant to others non-exclusive licenses to make and use for NON-COMMERCIAL RESEARCH PURPOSES the
subject matter described and claimed in PATENT RIGHTS. 

  

	 	(c)	 LICENSEE shall use diligent efforts to effect introduction of the LICENSED PRODUCTS into the commercial market as soon as practicable, consistent
with sound and reasonable business practice and judgment; thereafter, until the expiration of this Agreement, LICENSEE shall endeavor to keep LICENSED PRODUCTS reasonably available to the public. 

  

	 	(d)	 At any time after five (5) years from the EFFECTIVE DATE, HARVARD may terminate or render this license non-exclusive if, in HARVARD’s
reasonable judgment, the Progress Reports furnished by LICENSEE do not demonstrate that LICENSEE: 

  

	 	(i)	 has put the licensed subject matter into commercial use in the country or countries hereby licensed, directly or through a

  

 4 

	 	 
sublicense, and is not keeping the licensed subject matter reasonably available to the public, or 

  

	 	(ii)	 is engaged in research, development, manufacturing, marketing or sublicensing activity appropriate to achieving 3.3(d)(1), and

  

	 	(iii)	 has adhered directly or through a sublicensee to the following performance milestones: 

 1. Within five (5) years from the effective date, LICENSEE shall have designed and built at least one prototype device
based on PATENT RIGHTS and shall provide HARVARD with documentation of such. 
 2. Within seven (7) years
from the effective date, LICENSEE shall be manufacturing at least one device based on PATENT RIGHTS and shall provide HARVARD with documentation of such. 
 3. Within eight (8) years from the effective date, LICENSEE shall provide HARVARD with documentation of the commercial sale of at least one device or service based on PATENT RIGHTS. 
 LICENSEE will inform HARVARD promptly in writing about any material problem, delay or requirement in connection with the
commercial, development and/or manufacture, use, sale or marketing of LICENSED PRODUCTS. LICENSEE and HARVARD may modify the above performance milestones accordingly and as mutually agreed. 
  

	 	(e)	 In all sublicenses granted by LICENSEE hereunder, LICENSEE shall include a requirement that the sublicensee use its best efforts to bring the
subject matter of the sublicense into commercial use as quickly as is reasonably possible. LICENSEE shall further provide in such sublicenses that such sublicenses are subject and subordinate to the terms and conditions of this Agreement, except the
sublicensee may not further sublicense. Copies of all sublicense agreements shall be provided promptly to HARVARD. 

  

	 	(f)	 During the period of exclusivity of this license in the United States, LICENSEE shall cause any LICENSED PRODUCT produced for sale in the United
States to be manufactured substantially in the United States. 

  

	4.3	 All rights reserved to the United States Government and others under Public Law 96-517, and Public Law 98-620, shall remain and shall in no way be
affected by this Agreement. 

 ARTICLE V 
 ROYALTIES 
  

	5.1	 LICENSEE has paid to HARVARD a non-refundable license royalty fee in the sum of    ***    .

  

	5.2	 (a) Sales/Sublicenses in the Nucleic Acid Sensor Market: LICENSEE shall pay to HARVARD during the term of this Agreement a royalty
of    ***    of NET SALES by LICENSEE and sublicensees. In the case of sublicenses that are based solely on PATENT RIGHTS, LICENSEE shall also pay to
HARVARD    ***    of any NON-ROYALTY SUBLICENSE INCOME. Such additional payments shall only be due for sublicenses executed prior to the four year anniversary of the EFFECTIVE DATE. For any sublicense
agreement concluded after the four year anniversary of the EFFECTIVE DATE, and for any sublicense agreement that is not based solely on PATENT RIGHTS, there shall be no payments due based on NON-ROYALTY SUBLICENSE INCOME; however LICENSEE shall pay
to HARVARD a    ***    royalty on sublicensee NET SALES. 

 (b) Sales/Sublicenses in the Protein Sensor Market: LICENSEE shall pay to HARVARD during the term of this Agreement a royalty of    ***    of NET SALES by LICENSEE and a royalty
of    ***    of NET SALES by sublicensees. In the case of sublicenses that are based solely on PATENT RIGHTS or sublicenses which include both the Nucleic Acid Sensor Field and the Protein Sensor Field,
LICENSEE shall also pay to HARVARD    ***    of any NON-ROYALTY SUBLICENSE INCOME. In the case of sublicenses that are not based solely on PATENT RIGHTS, LICENSEE shall pay to
HARVARD    ***    of any NON-ROYALTY SUBLICENSE INCOME. Such additional payments shall only be due for sublicenses executed prior to the five year anniversary of the EFFECTIVE DATE. For sublicense agreement
executed after the five year anniversary of the EFFECTIVE DATE, there will be no payments based on NON-ROYALTY SUBLICENSE INCOME; however LICENSEE shall pay to HARVARD a    ***    royalty on sublicensee NET
SALES. 
 (i) If LICENSEE’s cumulative NET SALES on any one LICENSED PRODUCT
reach    ***    , LICENSEE may reduce the royalty due to HARVARD under this Section 5.2(b) from NET SALES of such LICENSED PRODUCT by    ***    to a final royalty
of    ***    . 
 (ii) If LICENSEE is required to obtain
license(s)/sublicense(s) for third party patents infringed as a result of practising the subject matter of PATENT RIGHTS, then royalties due HARVARD under this Section 5.2(b) will be reduced by an amount equivalent to the royalty payable to
such third party(s) (“Infringing Royalty”); however, the royalty due HARVARD will not be reduced by more than    ***    . 
  

	***	 Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.

 (iii) If royalties are paid by LICENSEE to an entity (other than an
AFFILIATE) for LICENSED PRODUCT OR LICENSED PROCESSES for which royalties are also due to HARVARD under this Section 5.2(b) (“Other Royalties”) and total royalties excluding Infringing Royalty for a LICENSED PRODUCT or LICENSED
PROCESS exceed    ***    of NET SALES, then the royalties due to HARVARD shall be reduced by    ***     for each    ***    , but
only to the extent that the Other Royalties, which are equal to or greater than the royalty due to HARVARD, are reduced in a like manner. The royalty due HARVARD shall never be reduced by more
than    ***    in any one year. These reductions may not be accumulated and carried over into future years. 
 (iv) In no event may the royalty payable to HARVARD under this Section 5.2(b) be reduced below    ***    as a result of all the reductions of Sections 5.2(b)
(i)-(iii). 
 (c) Only one royalty for each specific sale of a LICENSED PRODUCT shall be payable irrespective of
the number of patents or patent applications in PATENT RIGHTS covering the manufacture, use or sale of such LICENSED PRODUCTS. 
 (d) If the license pursuant to this Agreement is converted to a non-exclusive one and if other non-exclusive licenses in the same field and territory are granted, the above royalties shall not exceed the
royalty rate to be paid by other licensees in the same field and territory during the term of the non-exclusive license. 
 (e) On sales between LICENSEE and its AFFILIATES or sublicensees for resale, the royalty shall be paid on the NET SALES of the AFFILIATE or sublicensee. 
  

	5.3	 No later than sixty (60) days from January 1 of each calendar year after the effective date of this Agreement, LICENSEE shall pay to
HARVARD the following non-refundable license maintenance royalty and/or advance on royalties. Such payments may be credited against running royalties due for that calendar year and Royalty Reports shall reflect such a credit. Such payments shall not
be credited against milestone payments (if any) nor against royalties due for any subsequent calendar year. 

  

									
		 	 February 28,1998
	 	***	  		  	
		 	 February 28,1999
	 	***	  		  	
		 	 February 28,2000 and each year thereafter
	 	***	  		  	

  

	***	 Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.

 ARTICLE VI 
 REPORTING 
  

	6.1	 Prior to signing this Agreement, LICENSEE has provided to HARVARD a written research and development plan under which LICENSEE intends to bring the
subject matter of the licenses granted hereunder into commercial use upon execution of this Agreement. 

  

	6.2	 No later than February 28 of each calendar year, LICENSEE shall provide to HARVARD a written annual Progress Report describing progress on
research and development, regulatory approvals, manufacturing, sublicensing, marketing and sales during the preceeding calendar year and plans for the forthcoming year. If multiple technologies are covered by the license granted hereunder, the
Progress Report shall provide the information set forth above for each technology. LICENSEE shall also provide any reasonable additional data HARVARD requires to evaluate LICENSEE’s performance. 

  

	6.3	 LICENSEE shall report to HARVARD the date of first sale of LICENSED PRODUCTS (or results of LICENSED PROCESSES) in each country within thirty
(30) days of occurrence. 

  

	6.4	 (a) LICENSEE shall submit to HARVARD on or before February 28 of each calendar year, a Royalty Report setting forth for such preceeding year at
least the following information: 

  

	 	(i)	 the number of LICENSED PRODUCTS sold by LICENSEE, its AFFILIATES and sublicensees in each country; 

  

	 	(ii)	 total billings for such LICENSED PRODUCTS; 

  

	 	(iii)	 an accounting for all LICENSED PROCESSES used or sold; 

  

	 	(iv)	 deductions applicable to determine the NET SALES thereof; 

  

	 	(v)	 the amount of NON-ROYALTY SUBLICENSE INCOME received by LICENSEE; and 

  

	 	(vi)	 the amount of royalty due thereon, or, if no royalties are due to HARVARD for any reporting period, the statement that no royalties are due.

 Such report shall be certified as correct by an officer of LICENSEE and shall include a
detailed listing of all deductions from royalties. 
  

	(b)	 LICENSEE shall pay to HARVARD with each such Royalty Report the amount of royalty due with respect to such year. If multiple technologies are
covered by the license granted hereunder, LICENSEE shall specify which PATENT RIGHTS

	 	 
are utilized for each LICENSED PRODUCT and LICENSED PROCESS included in the Royalty Report. 

  

	(c)	 All payments due hereunder shall be deemed received when funds are credited to Harvard’s bank account and shall be payable by check or wire
transfer in United States dollars. Conversion of foreign currency to U.S. dollars shall be made at the conversion rate existing in the United States (as reported in the New York Times or the Wall Street Journal) on the last working day of each
royalty period. No transfer, exchange, collection or other charges shall be deducted from such payments. 

  

	(d)	 All such reports shall be maintained in confidence by HARVARD except as required by law; however, HARVARD may include in its usual reports annual
amounts of royalties paid. 

  

	(e)	 Late payments shall be subject to a charge of    ***    whichever is greater. 

ARTICLE VII 
 RECORD KEEPING 
  

	7.1	 LICENSEE shall keep, and shall require its AFFILIATES and sublicensees to keep, accurate records (together with supporting documentation) of
LICENSED PRODUCTS made, used or sold under this Agreement, appropriate to determine the amount of royalties due to HARVARD hereunder. Such records shall be retained for at least three (3) years following the end of the reporting period to which
they relate. They shall be available during normal business hours for examination by an accountant selected by HARVARD, for the sole purpose of verifying reports and payments hereunder. In conducting examinations pursuant to this paragraph,
HARVARD’s accountant shall have access to all records which HARVARD reasonably believes to be relevant to the calculation of royalties under Article IV. 

  

	7.2	 HARVARD’s accountant shall not disclose to HARVARD any information other than information relating to the accuracy of reports and payments made
hereunder. 

  

	7.3	 Such examination by HARVARD’s accountant shall be at HARVARD’S expense, except that if such examination shows an underreporting or
underpayment in excess of five percent (5%) for any twelve (12) month period, then LICENSEE shall pay the cost of such examination as well as any additional sum that would have been payable to HARVARD had the LICENSEE reported correctly,
plus interest on said sum at the rate of one and one half per cent (11/2%) per month. 

  

	***	 Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.

 ARTICLE VIII 
 DOMESTIC AND FOREIGN PATENT FILING AND MAINTENANCE 
  

	8.1	 Within sixty (60) days of the execution of this Agreement, LICENSEE shall reimburse HARVARD for all reasonable expenses HARVARD has incurred
for the preparation, filing, prosecution and maintenance of PATENT RIGHTS. Thereafter, LICENSEE shall reimburse HARVARD for all such future expenses upon receipt of invoices from HARVARD. Late payment of these invoices shall be subject to interest
charges of    ***    per month. HARVARD shall, in its sole discretion, be responsible for the preparation, filing, prosecution and maintenance of any and all patent applications and patents included in PATENT
RIGHTS. HARVARD shall consult with LICENSEE as to the preparation, filing, prosecution and maintenance of such patent applications and patents and shall furnish to LICENSEE copies of documents relevant to any such preparation, filing, prosecution or
maintenance. 

  

	8.2	 Upon receipt of LICENSEE’s payment of expenses incurred for the preparation, filing, prosecution and maintenance of PATENT RIGHTS according to
8.1, HARVARD shall provide to LICENSEE copies of the complete file history for all patents and patent applications in PATENT RIGHTS. 

  

	8.3	 HARVARD and LICENSEE shall cooperate fully in the preparation, filing, prosecution and maintenance of PATENT RIGHTS and of all patents and patent
applications licensed to LICENSEE hereunder, executing all papers and instruments or requiring members of HARVARD to execute such papers and instruments so as to enable HARVARD to apply for, to prosecute and to maintain patent applications and
patents in HARVARD’s name in any country. Each party shall provide to the other prompt notice as to all matters which come to its attention and which may affect the preparation, filing, prosecution or maintenance of any such patent applications
or patents. 

  

	8.4	 LICENSEE may elect to surrender its PATENT RIGHTS in any country upon sixty (60) days written notice to HARVARD. Such notice shall not relieve
LICENSEE from responsibility to reimburse HARVARD for patent-related expenses incurred prior to the expiration of the (60)-day notice period (or such longer period specified in LICENSEE’S notice). 

 ARTICLE IX 
 INFRINGEMENT 
  

	9.1	 With respect to any PATENT RIGHTS that are exclusively licensed to LICENSEE pursuant to this Agreement, LICENSEE shall have the right to prosecute
in its own name and at its own expense any infringement in the FIELD

  

	***	 Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.

	 	 
of such patent, so long as such license is exclusive in the FIELD at the time of the commencement of such action. HARVARD agrees to notify LICENSEE promptly of each infringement of such patents
of which HARVARD is or becomes aware. Before LICENSEE commences an action with respect to any infringement of such patents, LICENSEE shall give careful consideration to the views of HARVARD and to potential effects on the public interest in making
its decision whether or not to sue. 

  

	9.2	 (a) If LICENSEE elects to commence an action as described above, Harvard may, to the extent permitted bylaw, elect to join as a party in that
action. Regardless of whether HARVARD elects to join as a party, HARVARD shall cooperate fully with LICENSEE in connection with any such action. 

  

	 	(b)	 If HARVARD elects to join as a party pursuant to subparagraph (a), HARVARD shall jointly control the action with LICENSEE.

  

	 	(c)	 LICENSEE shall reimburse HARVARD for any costs HARVARD incurs, including reasonable attorneys’ fees, as part of an action brought by LICENSEE,
irrespective of whether HARVARD becomes a co-plaintiff. 

  

	9.3	 If LICENSEE elects to commence an action as described above, LICENSEE may deduct from its royalty payments to HARVARD with respect to the patent(s)
subject to suit an amount not exceeding     ***     of LICENSEE’s expenses and costs of such action, including reasonable attorneys’ fees; provided, however, that such reduction shall not
exceed    ***    of the total royalty due to HARVARD with respect to the patent(s) subject to suit for each calendar year. If such    ***    of LICENSEE’s expenses
and costs exceeds the amount of royalties deducted by LICENSEE for any calendar year, LICENSEE may to that extent reduce the royalties due to HARVARD from LICENSEE in succeeding calendar years, but never by more
than    ***    of the total royalty due in any one year with respect to the patent(s) subject to suit. 

  

	9.4	 No settlement, consent judgment or other voluntary final disposition of the suit may be entered into without the prior written consent of HARVARD,
which consent shall not be unreasonably withheld. 

  

	9.5	 Recoveries or reimbursements from actions commenced pursuant to this Article shall first be applied to reimburse LICENSEE and HARVARD for litigation
costs not paid from royalties and then to reimburse HARVARD for royalties deducted by LICENSEE pursuant to paragraph 8.3. Any remaining recoveries or reimbursements shall be shared as follows: 

 (i) If the amount is lost profits, LICENSEE shall receive an amount equal to the damages the court determines LICENSEE has
suffered as a result of the infringement less the amount of any royalties that would have been due HARVARD on sales of LICENSED PRODUCTS lost by LICENSEE as a result

  

	***	 Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.

 
of the infringement had LICENSEE made such sales and HARVARD shall receive    ***    have received if such sales had been made by LICENSEE; or 

(ii) As to awards other than lost profits,    ***    to LICENSEE
and    ***    to HARVARD. 
  

	9.6	 If LICENSEE elects not to exercise its right to prosecute an infringement of the PATENT RIGHTS pursuant to this Article, HARVARD may do so at its
own expense, controlling such action and retaining all recoveries therefrom. LICENSEE shall cooperate fully with HARVARD in connection with any such action. Any reasonable legal expenses incurred by LICENSEE as a direct result of such cooperation
shall be reimbursed from HARVARD’s recoveries. 

  

	9.7	 Without limiting the generality of paragraph 9.6, HARVARD may, at its election and by notice to LICENSEE, establish a time limit of sixty
(60) days for LICENSEE to decide whether to prosecute any infringement of which HARVARD is or becomes aware. If, by the end of such sixty (60)-day period, LICENSEE has not commenced such an action, HARVARD may prosecute such an infringement at
its own expense, controlling such action and retaining all recoveries therefrom. With respect to any such infringement action prosecuted by HARVARD in good faith, LICENSEE shall pay over to Harvard any payments (whether or not designated as
“royalties”) made by the alleged infringer to LICENSEE under any existing or future sublicense authorizing LICENSED PRODUCTS, up to the amount of HARVARD’s unreimbursed litigation expenses (including, but not limited to, reasonable
attorneys’ fees). 

  

	9.8	 If a declaratory judgment action is brought naming LICENSEE as a defendant and alleging invalidity of any of the PATENT RIGHTS, HARVARD may elect to
take over the sole defense of the action at its own expense. LICENSEE shall cooperate fully with HARVARD in connection with any such action. 

  

	9.9	 In the event that an action is brought against LICENSEE or any of its sublicensees alleging direct infringement of a patent right due to the
manufacture, use, offer for sale or sale of LICENSED PRODUCTS, LICENSEE may terminate this Agreement upon giving HARVARD written notice of termination. In the event LICENSEE chooses not to terminate this Agreement, LICENSEE and HARVARD shall consult
and decide uon an appropriate course of action regarding defence of the action and payment of royalties. 

  

	***	 Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.

 ARTICLE X 
 TERMINATION OF AGREEMENT 
  

	10.1	 This Agreement, unless terminated as provided herein, shall remain in effect until the last patent or patent application in PATENT RIGHTS has
expired or been abandoned. 

  

	10.2	 HARVARD may terminate this Agreement as follows: 

  

	 	(a)	 If LICENSEE does not make a payment due hereunder and fails to cure such non-payment (including the payment of interest in accordance with paragraph
6.4(e)) within forty-five (45) days after the date of notice in writing of such non-payment by HARVARD. 

  

	 	(b)	 If LICENSEE defaults in its obligations under paragraph 11.3(c)and(d) to procure and maintain insurance. 

  

	 	(c)	 If, at any time after five years from the date of this Agreement, HARVARD determines that the Agreement should be terminated pursuant to paragraph
4.2(d). 

  

	 	(d)	 If LICENSEE shall become insolvent, shall make an assignment for the benefit of creditors, or shall have a petition in bankruptcy filed for or
against it. Such termination shall be effective immediately upon HARVARD giving written to LICENSEE. 

  

	 	(e)	 If an examination by Harvard’s accountant pursuant to Article VII shows a repeated pattern of fraudulent underreporting or underpayment by
LICENSEE in excess of    ***    for any twelve (12) month period. 

  

	 	(f)	 If LICENSEE is convicted of a felony and has exhausted its appeals to such conviction relating to the manufacture, use, or sale of LICENSED
PRODUCTS. 

  

	 	(g)	 Except as provided in subparagraphs (a), (b), (c), (d), (e) and (f) above, if LICENSEE defaults in the performance of any obligations
under this Agreement and the default has not been remedied within ninety (90) days after the date of notice in writing of such default by HARVARD. 

  

	10.3	 LICENSEE shall provide, in all sublicenses granted by it under this Agreement, that LICENSEE’s interest in such sublicenses shall at
HARVARD’s option terminate or be assigned to HARVARD upon termination of this Agreement. 

  

	10.4	 LICENSEE may terminate this Agreement by giving ninety (90) days advance written notice of termination to HARVARD. Upon termination, LICENSEE
shall

  

	***	 Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.

	 	 
submit a final Royalty Report to HARVARD and any royalty payments and unreimbursed patent expenses invoiced by HARVARD shall become immediately payable. 

  

	10.5	 Paragraphs 7.1, 7.2, 7.3, 8.1, 9.5, 10.4, 10.5, 11.2, 11.3, 11.4, 11.5, 11.8 and 11.9 of this Agreement shall survive termination.

 ARTICLE XI 
 GENERAL 
  

	11.1	 HARVARD does not warrant the validity of the PATENT RIGHTS licensed hereunder and makes no representations whatsoever with regard to the scope of
the licensed PATENT RIGHTS or that such PATENT RIGHTS may be exploited by LICENSEE, an AFFILIATE, or sublicensee without infringing other patents. 

  

	11.2	 HARVARD EXPRESSLY DISCLAIMS ANY AND ALL IMPLIED OR EXPRESS WARRANTIES AND MAKES NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR
ANY PARTICULAR PURPOSE OF THE PATENT RIGHTS, OR INFORMATION SUPPLIED BY HARVARD, LICENSED PROCESSES OR LICENSED PRODUCTS CONTEMPLATED BY THIS AGREEMENT. 

  

	11.3	 (a) LICENSEE shall indemnify, defend and hold harmless HARVARD and its current or former directors, governing board members, trustees, officers,
faculty, medical and professional staff, employees, students, and agents and their respective successors, heirs and assigns (collectively, the “Indemnitees”), against any liability, damage, loss or expenses (including reasonable
attorneys’ fees and expenses of litigation) incurred by or imposed upon the Indemnitees or any of them in connection with any claims, suits, actions, demands or judgments arising out of any theory of product liability (including, but not
limited to, actions in the form of tort, warranty, or strict liability) concerning any product, process or service made, used or sold pursuant to any right or license granted under this Agreement. 

  

	(b)	 LICENSEE shall, at its own expense, provide attorneys reasonably acceptable to HARVARD to defend against any actions brought or filed against any
Indemnitee hereunder with respect to the subject of indemnity contained herein, whether or not such actions are rightfully brought. 

  

	(c)	 Beginning at the time any such product, process or service is being commercially distributed or sold (other than for the purpose of obtaining
regulatory approvals) by LICENSEE or by a sublicensee, AFFILIATE or agent of LICENSEE, LICENSEE shall, at its sole cost and expense, procure and maintain commercial general liability insurance in amounts not less than
    ***    annual aggregate and naming the Indemnitees as additional insureds. During clinical

  

	***	 Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.

	 	 
trials of any such product, process or service, LICENSEE shall, at its sole cost and expense, procure and maintain commercial general liability insurance in such equal or lesser amount as HARVARD
shall require, naming the Indemnitees as additional insureds. Such commercial general liability insurance shall provide (i) product liability coverage and (ii) broad form contractual liability coverage for LICENSEE’S indemnification
under this Agreement. If LICENSEE elects to self-insure all or part of the limits described above (including deductibles or retentions which are in excess of    ***    ) such self-insurance program must be
acceptable to HARVARD and the Risk Management Foundation of the Harvard Medical Institutions, Inc. in their sole discretion. The minimum amounts of insurance coverage required shall not be construed to create a limit of LICENSEE’s liability
with respect to its indemnification under this Agreement. 

  

	(d)	 LICENSEE shall provide HARVARD with written evidence of such insurance upon request of HARVARD. LICENSEE shall provide HARVARD with written notice
at least fifteen (15) days prior to the cancellation, non-renewal or material change in such insurance; if LICENSEE does not obtain replacement insurance providing comparable coverage within such fifteen (15) day period, HARVARD shall have
the right to terminate this Agreement effective at the end of such fifteen (15) day period without notice or any additional waiting periods. 

  

	(e)	 LICENSEE shall maintain such commercial general liability insurance beyond the expiration or termination of this Agreement during (i) the
period that any product, process, or service, relating to, or developed pursuant to, this Agreement is being commercially distributed or sold by LICENSEE or by a sublicensee, AFFILIATE or agent of LICENSEE and (ii) a reasonable period after the
period referred to in (e)(i) above which in no event shall be less than fifteen (15) years. 

  

	11.4	 LICENSEE shall not use HARVARD’s name or insignia, or any adaptation of them, or the name of any of HARVARD’s inventors in any
advertising, promotional or sales literature without the prior written approval of HARVARD. 

  

	11.5	 HARVARD shall not use LICENSEE’s name or logos in any advertising or promotional literature without the prior written approval of LICENSEE, nor
may HARVARD disclose the financial terms of this Agreement without LICENSEE’s prior written approval, except as required by law. HARVARD may use LICENSEE’s name and royalty information in its own internal confidential reports.

  

	11.6	 Without the prior written approval of HARVARD in each instance, neither this Agreement nor the rights granted hereunder shall be transferred or
assigned in whole or in part by LICENSEE to any person whether voluntarily or involuntarily, by operation of law or otherwise. This Agreement shall be binding upon the respective successors, legal representatives and assignees of HARVARD and
LICENSEE. 

  

	***	 Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.

	11.7	 The interpretation and application of the provisions of this Agreement shall be governed by the laws of the Commonwealth of Massachusetts.

  

	11.8	 LICENSEE shall comply with all applicable laws and regulations. In particular, it is understood and acknowledged that the transfer of certain
commodities and technical data is subject to United States laws and regulations controlling the export of such commodities and technical data, including all Export Administration Regulations of the United States Department of Commerce. These laws
and regulations among other things, prohibit or require a license for the export of certain types of technical data to certain specified countries. LICENSEE hereby agrees and gives written assurance that it will comply with all United States laws
and regulations controlling the export of commodities and technical data, that it will be solely responsible for any violation of such by LICENSEE or its AFFILIATES or sublicensees, and that it will defend and hold HARVARD harmless in the event of
any legal action of any nature occasioned by such violation. 

  

	11.9	 LICENSEE agrees (i) to obtain all regulatory approvals required for the manufacture and sale of LICENSED PRODUCTS and LICENSED PROCESSES and
(ii) to utilize appropriate patent marking on such LICENSED PRODUCTS. LICENSEE also agrees to register or record this Agreement as is required by law or regulation in any country where the license is in effect. 

  

	11.10	 Any notices to be given hereunder shall be sufficient if signed by the party (or party’s attorney) giving same and either (a) delivered in
person, or (b) mailed certified mail return receipt requested, or (c) faxed to other party if the sender has evidence of successful transmission and if the sender promptly sends the original by ordinary mail, in any event to the following
addresses: 

 If to LICENSEE: 
 Jon Faiz Kayyem, PhD 
 President and CEO 
 Clinical Micro Sensors, Inc 
 101 Waverly Drive 
 Pasadena, CA 91105 
 Fax: 818-584-5900 
 If to Harvard to: 
 Office for Technology and 
 Trademark Licensing 
 Harvard University 
 124 Mt. Auburn Street, Suite 410 South 
 Cambridge, MA 02138

 Fax No.: 617-495-9568 
 By such notice either party may change their address for future notices. 

 Notices delivered in person shall be deemed given on the date delivered.
Notices sent by fax shall be deemed given on the date faxed. Notices mailed shall be deemed given on the date postmarked on the envelope. 
  

	11.11	 Should a court of competent jurisdiction later hold any provision of this Agreement to be invalid, illegal, or unenforceable, and such holding is
not reversed on appeal, it shall be considered severed from this Agreement. All other provisions, rights and obligations shall continue without regard to the severed provision, provided that the remaining provisions of this Agreement are in
accordance with the intention of the parties. 

  

	11.12	 This Agreement constitutes the entire understanding between the parties and neither party shall be obligated by any condition or representation
other than those expressly stated herein or as may be subsequently agreed to by the parties hereto in writing. 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their
duly authorized representatives. 
  

					
	 PRESIDENT AND FELLOWS OF
 HARVARD COLLEGE
	 		 	LICENSEE
			
	 /s/ Joyce Brinton
	 		 	 /s/ Jon Faiz Kayyem

	 Joyce Brinton, Director
 Office for Technology and Trademark Licensing
	 		 	Signature
			
		 		 	 Jon Faiz Kayyem, Ph.D.

		 		 	Name
			
		 		 	 President & CEO

		 		 	Title
			
	 1/7/98
	 		 	 January 13, 1998

	Date	 		 	Date

 Appendix A 
 The following comprise PATENT RIGHTS: 
 US patent application serial no.
08/312,388, filed 9/26/94, entitled “Molecular Recognition at Surfaces Derivatized with Self Assembled Monolayers” 
 Continuation-in-part of USSN 08/312,388 filed 1/21/97, serial no. 08/786,187 
 US patent application entitled
“Immobilized Nucleic Acid and Electron Transfer Devices or Methods”, filed 1/21/97, serial no. 08/786,153 (abd) 
 Continuation-in-part of US patent application filed 1/21/97 entitled “Immobilized Nucleic Acid and Electron Transfer Devices or Methods”, such CIP was filed on 2/24/97 and is entitled “Electronic-Property Probing of
Biological Molecules at Surfaces”, serial no. 08/804,883 (abd) 
 Continuation-in-part of US patent application filed
1/21/97 entitled “Immobilized Nucleic Acid and Electron Transfer Devices or Methods”, such CIP was filed on 4/10/97 and is entitled “Electronic-Property Probing of Biological Molecules at Surfaces”, serial no. 08/843,623

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}]]